Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.

Yan Li; Xiaomin Wang; Edward O’Mara; Meletios A Dimopoulos; Pieter Sonneveld; Katja C Weisel; Jeffrey Matous; David S Siegel; Jatin J Shah; Elisabeth Kueenburg; Lars Sternas; Chloe Cavanaugh; Mohamed Zaki; Maria Palmisano; Simon Zhou

doi:10.2147/CPAA.S144606

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.

Yan Li
, Xiaomin Wang
, Edward O’Mara
, Meletios A Dimopoulos
, Pieter Sonneveld
, Katja C Weisel
, Jeffrey Matous
, David S Siegel
, Jatin J Shah
, Elisabeth Kueenburg
, Lars Sternas
, Chloe Cavanaugh
, Mohamed Zaki
, Maria Palmisano
, Simon Zhou

Celgene
National and Kapodistrian University of Athens
Erasmus University Rotterdam
Department of Hematology, University Hospital Tübingen, Tübingen, Germany.
Department of Hematology/Oncology, Colorado Blood Cancer Institute, Denver, CO, USA.
Hackensack University Medical Center
University of Texas MD Anderson Cancer Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Pharmacology: Advances and Applications
Volume	9
DOIs	https://doi.org/10.2147/CPAA.S144606
State	Published - Nov 8 2017
Externally published	Yes

Disciplines

Medicine and Health Sciences
Urology

Access to Document

10.2147/CPAA.S144606License: Unspecified

Cite this

Li, Y., Wang, X., O’Mara, E., Dimopoulos, M. A., Sonneveld, P., Weisel, K. C., Matous, J., Siegel, D. S., Shah, J. J., Kueenburg, E., Sternas, L., Cavanaugh, C., Zaki, M., Palmisano, M., & Zhou, S. (2017). Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. Clinical Pharmacology: Advances and Applications, 9. https://doi.org/10.2147/CPAA.S144606

Li, Y, Wang, X, O’Mara, E, Dimopoulos, MA, Sonneveld, P, Weisel, KC, Matous, J, Siegel, DS, Shah, JJ, Kueenburg, E, Sternas, L, Cavanaugh, C, Zaki, M, Palmisano, M & Zhou, S 2017, 'Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.', Clinical Pharmacology: Advances and Applications, vol. 9. https://doi.org/10.2147/CPAA.S144606

@article{be8dbcb6ea1a4097bd6c401d00ef013f,

title = "Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.",

author = "Yan Li and Xiaomin Wang and Edward O{\textquoteright}Mara and Dimopoulos, \{Meletios A\} and Pieter Sonneveld and Weisel, \{Katja C\} and Jeffrey Matous and Siegel, \{David S\} and Shah, \{Jatin J\} and Elisabeth Kueenburg and Lars Sternas and Chloe Cavanaugh and Mohamed Zaki and Maria Palmisano and Simon Zhou",

year = "2017",

month = nov,

day = "8",

doi = "10.2147/CPAA.S144606",

language = "American English",

volume = "9",

journal = "Clinical Pharmacology: Advances and Applications",

}

TY - JOUR

T1 - Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.

AU - Li, Yan

AU - Wang, Xiaomin

AU - O’Mara, Edward

AU - Dimopoulos, Meletios A

AU - Sonneveld, Pieter

AU - Weisel, Katja C

AU - Matous, Jeffrey

AU - Siegel, David S

AU - Shah, Jatin J

AU - Kueenburg, Elisabeth

AU - Sternas, Lars

AU - Cavanaugh, Chloe

AU - Zaki, Mohamed

AU - Palmisano, Maria

AU - Zhou, Simon

PY - 2017/11/8

Y1 - 2017/11/8

UR - https://repub.eur.nl/pub/103165/REPUB_103165-OA.pdf

U2 - 10.2147/CPAA.S144606

DO - 10.2147/CPAA.S144606

M3 - Article

VL - 9

JO - Clinical Pharmacology: Advances and Applications

JF - Clinical Pharmacology: Advances and Applications

ER -

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.

Disciplines

Access to Document

Other files and links

Cite this